Rating History for Alexion Pharmaceuticals (ALXN) by Baird
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 12/14/2020 | Michael Ulz | Downgrade | Neutral (Outperform) |
175.00 (N/A) |
118.87 (182.01) |
53.12% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 12/14/2020 | Michael Ulz | Downgrade | Neutral (Outperform) |
175.00 (N/A) |
118.87 (182.01) |
53.12% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||